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Boulogne sur Mer, France
Bone marrow adipose tissue (BMAT) emerges as a distinct fat depot whose importance 
has been proved in the bone–fat interaction. Indeed, it is well recognized that adipokines 
and free fatty acids released by adipocytes can directly or indirectly interfere with cells of 
bone remodeling or hematopoiesis. In pathological states, such as osteoporosis, each 
of adipose tissues  –  subcutaneous white adipose tissue (WAT), visceral WAT, brown 
adipose tissue (BAT), and BMAT –  is differently associated with bone mineral density 
(BMD) variations. However, compared with the other fat depots, BMAT displays striking 
features that makes it a substantial actor in bone alterations. BMAT quantity is well asso-
ciated with BMD loss in aging, menopause, and other metabolic conditions, such as 
anorexia nervosa. Consequently, BMAT is sensed as a relevant marker of a compromised 
bone integrity. However, analyses of BMAT development in metabolic diseases (obesity 
and diabetes) are scarce and should be, thus, more systematically addressed to better 
apprehend the bone modifications in that pathophysiological contexts. Moreover, bone 
marrow (BM) adipogenesis occurs throughout the whole life at different rates. Following 
an ordered spatiotemporal expansion, BMAT has turned to be a heterogeneous fat depot 
whose adipocytes diverge in their phenotype and their response to stimuli according to 
their location in bone and BM. In vitro, in vivo, and clinical studies point to a detrimental 
role of BM adipocytes (BMAs) throughout the release of paracrine factors that modulate 
osteoblast and/or osteoclast formation and function. However, the anatomical dissemi-
nation and the difficulties to access BMAs still hamper our understanding of the relative 
contribution of BMAT secretions compared with those of peripheral adipose tissues. 
A further characterization of the phenotype and the functional regulation of BMAs are 
ever more required. Based on currently available data and comparison with other fat 
tissues, this review addresses the originality of the BMAT with regard to its development, 
anatomy, metabolic properties, and response to physiological cues.
Keywords: fat–bone association, marrow fat, adipokine, bone marrow adiposity, skeletal adipocyte, osteoporosis, 
bone fragility
Besides being the main energy storage sites, adipose tissues have revealed through these last decades 
their diversity regarding their cellular composition, anatomical location, and pathophysiological 
properties. Indeed, adipocytes are typically classified into three categories: white, brown, and beige 
types (1). White adipocytes store excessive energy supply in a unilocular triglyceride droplet to 
release fatty acids in periods of energy depletion. White adipocytes also exert an endocrine function 
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through the secretions of various adipokines that mainly regulate 
metabolism and inflammation (2). Conversely, brown adipocytes 
are multilocular, rich in mitochondria, and dissipate the energy 
into heat through the uncoupling protein-1 (UCP-1). Their high 
glucose uptake and oxidative capacities make them key players in 
the energy balance. At last, beige (also called “brite”) adipocytes 
are brown-like adipocytes with UCP-1 expression that arise 
within white fat depots in response to cold or catecholaminergic 
stimulation (3).
Most adipose tissues in adult humans consist of white adipose 
tissue (WAT) that encompasses major subcutaneous depots 
(85% of total adipose tissue) in the lower or abdominal body 
parts and visceral fat depots (~10%) with omental, mesenteric, 
or retroperitoneal distributions. According to that anatomical 
location and the pathophysiological contexts, WATs exhibit 
differences in their development pattern, lipogenic and lipolytic 
activities, “browning” ability, or endocrine functions. This is best 
exemplified by the development of visceral adipose tissue that 
is considered as a strong predictive factor for the emergence of 
obesity co-morbidities, notably through the secretion of pro-
inflammatory cytokines and an enhanced lipolysis (4). Brown 
adipose tissue (BAT) exhibits a more diffuse distribution with 
discrete small depots. Owing to the recent reassessement of BAT 
in adults, stimulating BAT and beige adipocyte recruitment have 
become promising strategies for the management of metabolic 
diseases (3, 5).
In addition to WAT and BAT, bone marrow adipose tissue 
(BMAT) emerges as a “new” fat depot that could represent up 
to 5% of total fat mass in adults. The presence of BMAT – also 
referred to as “yellow” bone marrow (BM) – was of a long-standing 
knowledge but has been surprisingly disregarded for many decades. 
Meanwhile, bone has been revealed as a target and a regulator of 
energy metabolism: the two main adipokines, adiponectin and 
leptin, modulate bone mass through indirect and direct mecha-
nisms (6, 7) and undercarboxylated osteocalcin, the bone-derived 
hormone, positively impacts on whole-body glucose metabolism 
(8, 9). Moreover, numerous clinical studies indicate strong rela-
tionships between BMAT amount and bone loss emphasizing its 
potential pathophysiological role in osteoporosis. Other lines of 
evidence support the involvement of BMAT in hematopoiesis 
regulation (10) and in the pathophysiology of myeloma (11) and 
bone metastases (12). Such bone–fat connections have contrib-
uted to renew interest in BMAT. Yet, the anatomical dissemina-
tion of BM fat and the difficulties to study adipocytes inside bones 
have considerably hampered our understanding of BM adipocyte 
(BMA) function and its relative contribution to pathophysiologi-
cal processes compared with extramedullary fat depots. In this 
review, we aim at highlighting the current knowledge of BMAT 
development and phenotype to pinpoint its original features as 
an adipose tissue.
BMAT DeveLOPMeNT iS BOTH 
PHYSiOLOGiCAL AND PATHOLOGiCAL
exploration of BMAT Development
The first descriptions of “hematopoietic red BM” replacement 
by the “fat yellow BM” were brought by histomorphometric 
studies of iliac crest biopsies in humans (13, 14) or other bone 
sites in animals. BMAT quantification has been, thus, performed 
using specific but static parameters (adipocyte number and 
diameter, percent of adipocyte volume per tissue volume), which 
precludes a reliable and dynamic assessment of adipocyte evolu-
tion according to the pathophysiological conditions. Magnetic 
resonance imaging (MRI) has been being of considerable inter-
est to map non-invasively the distribution of hematopoietic 
BM and fatty BM in clinical studies (15). Moreover, proton 
magnetic resonance spectroscopy (1H MRS) allows the rela-
tive assessment of the saturated and unsaturated fatty acid 
composition of the fat fraction to monitor the lipid content 
changes. Combined with bone mineral density (BMD) and 
bone structure measurement by dual energy X-ray absorpti-
ometry (DEXA) and high-resolution peripheral quantitative 
computed tomography, respectively, MR techniques have 
been being instrumental to follow BMAT development and 
to evaluate relationship between bone quantity and BMAT 
amount in diverse cohorts. Finally, using the lipid affinity 
of the opaque agent osmium tetroxide, a three-dimensional 
quantification of BMAT (whole amount, individual volume, 
spatial distribution) can be achieved by micro- or nanocom-
puterized tomography (μCT, nanoCT) in animal decalcified 
bones (16).
Physiological BM Cellular  
Conversion to BMAT
Bone marrow adiposity development has been shown to be age, 
bone site, and gender dependent. At birth, bone cavities mainly 
contain active hematopoietic red marrow. BMAT accretion then 
occurs in an orderly and centripetal way: the process begins in the 
terminal phalanges around birth, continues in the appendicular 
skeleton (from the diaphysis to the distal and proximal extremi-
ties of the long bones) and finally arises in the axial skeleton 
(15, 17, 18). By the age of 25 years, BMAT is considered to occupy 
50 (17) to 70% (16) of the BM volume, while hematopoietic BM 
is mainly restricted to the axial skeleton, ribs, sternum, and 
proximal metaphyses of humerus and femur. Afterward, the BM 
conversion into BMAT slowly progresses throughout the adult-
hood. Interestingly, women exhibit less BMAT amount compared 
with age-matched men (19, 20) prior the menopause age, while 
the following period is associated with a sharp increase of BM 
adiposity (21).
The development pattern in rodents is considered to be 
similar though it is far to be as well characterized as in humans. 
Histological studies of femur or tibia show the presence of 
BMA at adult age (22, 23), which further increases with aging 
(24, 25). Of note, the percentage of BM adiposity (or BMA 
density) appears low in rodents when compared with humans 
and varies according to the mouse strain. Moreover the pres-
ence of different BMA subsets could be suspected from early 
(26) to more recent studies (27, 28). However, it is with the 
new introduction of osmium tetroxide staining combined with 
μCT visualization that analysis of BMAT development has led 
to the first characterization of two BMA subpopulations in 
rodents (29). Scheller and collaborators propose to distinguish 
constitutive BMA (cBMA) – which arise first and early in life 
TABLe 1 | Comparison of the main characteristics of brown adipose tissue 
(BAT), white adipose tissues (wAT), and bone marrow adipose tissue 
(BMAT) in rodents.
BAT wAT BMAT
Main  
locations
Interscapular (32) Subcutaneous 
(inguinal) and visceral 
(perigonadal > 
mesenteric >  
retro-peritoneal)  
(32)
Constitutive BMA 
(cBMA): distal tibia 
and caudal vertebrae
Regulated BMA 
(rBMA): proximal 
tibia and long bones, 
lumbar vertebrae (29)
Mean 
adipocyte 
diameter
– For rata For rata
~56 μm for inguinal ~40 μm for caudal 
cBMA
~74 μm for 
perigonadal
~33 μm for tibia 
rBMA
Amount 
variation  
during
Aging  with “whitening” 
 activity (33)
Subcutaneous   (mainly rBMA) 
(25, 29)Visceral  (33)
Calorie 
restriction 
(30%)
 (34, 35) Subcutaneous   (mainly rBMA) 
(22, 34, 35)Visceral  (34, 35) or 
unchanged (22, 35)
Cold  
exposure
 Subcutaneous  
with beiging  
(36, 37)
rBMA 
 activity (36, 37) cBMA  (29)
High-fat 
diet-induced 
obesity
 with “whitening” 
 activity (38)
Subcutaneous   (reported for 
rBMA in long bones) 
(39–41)
Visceral  (39, 40)
Ovariectomy  Subcutaneous   (reported for rBMA 
in long bones) (27) activity (42) Visceral  (42)
aValues from Sprague Dawley female rats aged between 19 and 24 weeks (29, 43).
 refers to “increased,”  refers to “decreased,”  refers to “unchanged.” “Whitening” 
refers to BAT with a changed morphology as occurrence of unilocular adipocytes with 
increased triglyceride storage. “Beiging” refers to WAT with a changed morphology as 
the occurrence of multilocular adipocytes with UCP-1 expression.
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in distal tibia and caudal vertebrae to constitute a rather dense 
fat depot  –  from regulated BMA (rBMA) whose formation is 
late, increases with age, and occurs in a more scattered way 
in the proximal tibia, distal femur, and lumbar vertebrae (29). 
Importantly, this distinction based on a spatiotemporal distri-
bution also corresponds to a different metabolic pattern and to 
different bone remodeling regions (see ‘‘Specific properties of 
BMA versus other adipocytes’’). How such classification can be 
extrapolated to humans is still difficult although one can suggest 
that cBMA reside in the feet and hands, whereas the rBMA 
develops in the proximal femur and lumbar vertebrae (16, 29).
BMAT Development Differs from that 
of extramedullary Adipose Tissues
Formed during gestation, BAT quantity and activity are 
maximal at birth to provide an efficient thermogenesis during 
the first weeks. Beyond puberty that is characterized by an 
important BAT activity, cold-activated BAT incidence remains 
high in young adults but rapidly declines by the age of 30 to 
almost disappear in the elderly (30). BAT function and WAT 
browning also decrease with age in rodents (31) as shown in 
Table 1. Thus, the development pattern of BMAT differs from 
the recruitment of thermogenic adipose tissues during the 
lifespan and other physiological conditions [exercice, cold 
exposure (3, 5)], supporting that BMAT development responds 
to different cues.
Early WAT formation is achieved through two early periods 
of intense precursor proliferation with adipocyte differentiation 
and lipogenesis in the meanwhile. By the end of adolescence, an 
adipocyte number set point specific to each individual is consid-
ered to be reached and to remain constant throughout life (44), 
with a rather low adipocyte renewal rate estimated at 8% per year 
(45). Indeed, the tremendous expandability of WAT primarily 
relies on adipocyte hypertrophy (cell size increase). Hyperplasia 
(cell number increase) occurs secondly when adipocyte storage 
capacity is exceeded and preferentially in subcutaneous AT. WAT 
growth is, thus, observed throughout the adult lifespan with a 
maximal mass achieved at middle–early old age. In advanced old 
age, white fat depots are redistributed with a subcutaneous fat loss 
in favor of visceral fat accumulation and ectopic fat deposition 
in other tissues (46). BMAT development with its long-lasting 
hyperplasia and concomitant hypertrophy (14) throughout 
life exhibits some striking differences compared with WAT. 
Moreover, BMAT amount is generally not correlated to usual 
anthropometric parameters of adiposity, such as waist-to-hip 
ratio, amount of visceral or subcutaneous fat, or even body mass 
index (47–49). Altogether, BMAT formation also appears inde-
pendently regulated from extramedullary WAT both in humans 
and rodents (Table 1).
Adipose Tissues and Relationship 
with Skeletal Fragility: The importance 
of BMAT Development
Beyond being a simple witness of age, diffuse or local BMAT 
accumulation has been described in several types of osteopo-
rosis notably that associated with aging, menopause, anorexia 
nervosa, or glucocorticoid treatment. In humans, BMAT 
amount is even found inversely correlated with bone quantity 
in aged (47, 50), post-menopausal (51), and anorexia nervosa 
(52) subjects at various bone sites. Enhanced BMAT formation 
is also depicted in animal models of aging (53), ovariectomy 
(27), calorie restriction (22), or following glucocorticoid admin-
istration (54). Bone loss results from an altered bone remodeling 
with either decreased number and/or mineralizing function of 
osteoblasts as in senile osteoporosis, or with increased bone 
resorption by osteoclasts that overwhelms bone formation as 
in post-menopausal osteoporosis (55). BMAT is suspected to 
contribute to this unbalanced bone remodeling through the 
adipogenesis process per se or its paracrine activity (see Section 
‘‘BM Adipogenesis’’ and ‘‘Specific Properties of BMA’’). However, 
it has to be emphasized that blocking BMAT formation failed to 
generate any bone modification in some mouse models (56, 57).
The impact of other adipose tissues on bone has of course 
been the subject of intensive clinical research that led to a 
complex picture. Whereas inconsistent results are drawn with 
subcutaneous adipose tissue measurements, visceral adipose 
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tissue level, when directly quantitated, is often found negatively 
associated with BMD and bone quality (58). Indeed, excess 
visceral fat as in obesity is paralleled by an altered adipokine 
secretion with increased pro-inflammatory cytokines that 
have been suggested to interfere with bone remodeling (59). 
A positive association between BAT volume and BMD has 
been reported in a few studies in humans (60–62). Yet the 
prevalence and activity of BAT in humans remain difficult to 
measure. The beneficial impact of active BAT on bone has also 
been reported in mouse models (63, 64) and could rely on 
direct [derived-BAT adipokines (64)] or indirect mechanisms 
(61, 63). Moreover, bone fragility is a comorbidity of several 
metabolic diseases and BMAT evolution is obviously of interest 
in that context.
BMAT Development in Metabolic Diseases
Regarding with type 1 diabetes, genetically or streptozotocin-
induced insulin deficiency results in increased BMAT in the long 
bones of mice (65). However, preventing BMAT formation does 
not impact on the bone loss (66) inherent to these models and the 
disease. Moreover, as reported in one study, BMAT content meas-
ured at different bone sites was unchanged in diabetic patients 
compared with control subjects (67). Thus, the involvement of 
BMAT in type 1 diabetes remains unclear and deserves further 
explorations.
The skeletal health in obesity has been a controversial subject 
(68, 69). However, most clinical and epidemiologic studies have 
reported an alteration of bone quality in obesity leading to an 
increased fracture incidence at specific bone sites (59, 70–72). 
Even though visceral adipose tissue quantity can be negatively 
associated with bone microarchitecture and strength (73), BMAT 
content has been poorly examined in obesity. So far, only one 
clinical study performed in obese premenopausal women has 
reported a positive correlation between visceral adiposity and 
vertebral BMAT (74). The Ob/Ob mouse model with extreme 
obesity due to spontaneous leptin disruption shows increased 
BM adipogenesis in the long bones (75). Nevertheless, this 
model remains complex to analyze because of the pleiotropic 
effects of leptin on bone and metabolism. The BMA amount in 
the long bones also increases in models of high-fat diet-induced 
obesity (39, 41, 76) (Table 1). However, divergent results make 
it difficult to conclude about the bone phenotype in these mod-
els and no associations have been drawn between metabolic 
parameters and the BMAT rise yet. Of note, animal age and 
diet duration appear to influence BMAT increment (41, 76), so 
that older mice would develop more quickly and at a higher 
level BMA.
Type 2 diabetic patients exhibit an increased fracture risk that 
is predominantly linked to a compromised bone quality (77, 78). 
In post-menopausal women, BMAT content in vertebrae is found 
unchanged by the diabetic state (79, 80), even though it is higher 
in patients who experienced prolonged hyperglycemia reflected 
by a HbA1c level above 7% (79).
Weight loss is well known to trigger bone loss, as exemplified 
in anorexia nervosa but also in bariatric surgery in obesity care 
(59). In anorexia nervosa (52), BMAT unexpectedly develops 
while subcutaneous and essentially visceral adipose tissues are 
extremely depleted. Bariatric surgery (81) or a 4-week-calorie 
restriction (82) in obese women leads to a marked or a more 
modest reduction of extramedullary fat depots, respectively. Yet, 
these decreases are not accompanied by significant changes in 
BMAT volume. These later studies rely on a limited number of 
subjects but suggest that the initial metabolic status [diabetes (81) 
or abdominal adipose tissue distribution (82)] can impact on the 
BMAT amount changes.
In summary, compared with other fat depots, BMAT could, 
thus, be considered as a strong and reliable indicator of bone integ-
rity that could open new clinical perspectives in the management 
of osteoporosis (83). Its measurement rather easily performed 
using MRI should be more systematically analyzed particularly in 
metabolic diseases considering that most available data have been 
generated in animal models. In response to metabolic variations, 
BMAT development differs from other fat depots in both humans 
and rodents. Yet, it remains conceivable that BMAT expansion 
may not be completely independent from the WAT distribution. 
In this connection, BMAT accretion could be triggered when 
WAT redistribution occurs as in aging. However, the paradoxical 
situation of anorexia nervosa supports that BMAT formation is 
dissociated from that of other fat tissues. A mechanistic pathway 
shared by all physiopathological conditions to explain BMAT 
development is, thus, still missing.
BM Adipogenesis
Bone marrow adipogenesis of resident mesenchymal stem 
cell (MSC) is classically controlled through a transcriptional 
cascade involving the key transcriptional factors PPARγ and 
c/EBPα. Within the BM, MSCs reside in the perivascular com-
partment, at the endosteal surface, and in the marrow space. 
As in other tissues, BM MSCs represent a heterogeneous cell 
population with regard to their cell surface marker expression 
and differentiation potential toward the osteoblast, adipocyte, 
or chondrocyte lineages (84, 85). It has to be emphasized that 
a great diversity of adipocyte precursors (distinct MSC popula-
tions, pericyte progenitors) for WAT and BAT has been revealed 
and debated this last decade (3, 44, 86). Interestingly, whereas 
most adipocytes also develop from adipose tissue-resident 
progenitors, engrafted BM-derived cells have been shown to 
generate new adipocytes within WAT in both humans (87) and 
rodents (88), which argues for another interaction between BM 
and WAT.
Importantly, adipogenesis is well considered as a competitive 
process for osteoblastogenesis within the BM. Haplo-insufficiency 
or overexpression of PPARγ in BM progenitor cells results in 
increased osteoblastogenesis or adipogenesis, respectively (89). 
Both in vitro and in vivo studies have shown that various condi-
tions – such as elevated glucocorticoid levels, estrogen withdrawal, 
oxidative stress, and immobilization  –  that promote adipogen-
esis limit osteoblastogenesis. Conversely, pro-osteogenic factors 
[growth hormone, insulin-like growth factor 1 (IGF1), Wnt pro-
teins, estrogens, mechanic inputs] decrease adipogenesis (85, 89, 
90). Thus, the BM MSC shift toward either lineage results from a 
complex interplay of systemic and local mediators.
However, the classical view of an unbalanced adipogenesis at 
the expense of osteoblastogenesis is challenged by other findings. 
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The coexistence within the mouse BM of independent precursor 
cells committed to each lineage has been shown (91). Both adi-
pocytes and osteoblasts can fully develop from mouse BM MSC 
in a co-differentiation medium without any alteration of either 
lineage (92). As described in Section “Physiological BM Cellular 
Conversion to BMAT,” a part of BMAT development occurs when 
the bone mass peak is achieved at human puberty and cBMA 
fully arise without bone loss in rodents. Bone mass can evolve 
independently of BM adipogenesis in some models (56, 57) or 
mouse strain (e.g., the C3H/HeJ strain) (93).
In this context, BMAT development cannot represent the only 
detrimental mechanism. BMA phenotype – which underlies its 
function – should be considered as a pivotal aspect in bone altera-
tions as emphasized below.
SPeCiFiC PROPeRTieS OF BMA veRSUS 
OTHeR ADiPOCYTeS
Basic Anatomy of the “BMAT”
Compared with subcutaneous or visceral fat lobules composed 
of ~80% well-packed adipocytes, BMAs arise loosely connected 
and scattered among hematopoietic cells. In that respect, such 
adipocyte distribution may not be referred to as a true “adipose 
tissue”. Whereas cBMA constitute a rather dense adipocyte area, 
rBMA are primarily located at the trabecular site where bone 
remodeling is active, which suggests their involvement in this 
process. The sympathetic cue is crucial in bone homeostasis (94) 
but the nerve distribution toward BMAs has not been depicted 
yet. Compared with hematopoietic areas, BMA-enriched regions 
are considered to be less vascularized with a lower perfusion as 
observed in the hip of normal-aged subjects (95). Moreover, vas-
cularization could differ between cBMA and rBMA areas with, 
surprisingly, a higher capillary density in the cBMA regions in 
mouse (96).
Bone marrow adipocytes appear filled by a large unilocular 
lipid vacuole, a typical morphology of white adipocytes. Human 
BMA diameter can vary from 40 to 65 μm according to the fat 
infiltration (14), the cellular composition of BM (97), or the 
analyzed age (14, 98). BMAs are, thus, smaller than subcutaneous 
and visceral adipocytes in both humans and rodents, with cBMA 
larger than rBMA (Table 1).
A white or Brown/Beige Phenotype?
Determining the white or brown/brite phenotype of BMA is 
crucial with regard to a better understanding of their regula-
tion and function. The development factors (Table  1) and the 
unilocular morphology of BMAs are more reminiscent of a white 
adipocyte. However, the preferential distribution of BM adiposity 
in the appendicular skeleton following a temperature gradient led 
some authors to propose a thermogenic role for the adipocytes 
(99, 100). Several gene markers specific for the “brown/beige” 
lineage were found expressed in the whole tibia BM in young 
mice. Based on the expression of both white and brown markers 
upon rosiglitazone treatment, although UCP-1 expression was 
barely detected, the authors proposed that BMAT has the two 
phenotypes (101). A high glucose uptake detected within the BM 
of cold-exposed patients combined with the immuno-detection 
of UCP-1 protein in the BMA of very young mice convincingly 
support the potential presence of functional brown/beige BMA 
in vertebrae (102). However, these results are contradicted by 
other studies. Several genes of the fatty acid oxidation pathway 
were found more weakly expressed in isolated BMA from long 
bones in comparison with isolated visceral adipocytes in mouse 
(23). Similarly, human BMA isolated from the iliac crest had 
lower mRNA levels of typical markers of the brown phenotype 
compared with subcutaneous adipocytes (103). Importantly, 
a long-term cold exposure of mice led to a marked decline of 
BMA density in tibiae but a concomitant browning of other WAT 
depots (29). Altogether, one may suggest that the BMA pheno-
type varies according to their localization: BMAs that arise in 
the long bones most likely belong to the white lineage, whereas 
some BMAs in the vertebrae can exhibit brown-like features. 
The presence of such thermogenic adipocytes could explain the 
disappearance of the “yellow BM” in the caudal vertebrae during 
a temperature rise (104). Indeed, hematopoiesis remains quite 
efficient in the vertebra BM and brown adipocytes have been 
proposed to support myelopoiesis through the secretion of some 
specific adipokines (102).
Most studies characterizing BMA have been performed from 
long bones or iliac crest samples and have raised some puzzling 
specificities regarding their paracrine/endocrine and metabolic 
properties.
Secretory Profile of BMA
The two main adipokines adiponectin and leptin are detected 
in isolated mature BMA, could locally promote osteoblastogen-
esis, and impact on osteoclastogenesis or hematopoiesis (89). 
However, their mRNA expression levels were found markedly 
low compared with extramedullary adipocytes in adult healthy 
donors (103) and normal-aged mice (23).This finding may 
relate to a lower state of differentiation of BMA as proposed in 
aging mice (23). Yet BMAT explants from rabbit (distal tibia) or 
human patients (tibia) were shown to secrete more adiponectin 
than other WAT depots. Moreover, through the characteriza-
tion of a mouse model of defective BM adipogenesis, BMAT 
was revealed as a significant source of serum adiponectin 
during caloric restriction (34). Even though this contribu-
tion to the calorie restriction-induced adiponectinemia rise 
was not confirmed in rabbits (35), this study underlies a true 
endocrine status of BMA which can modulate metabolism at 
the systemic level.
Given the importance of inflammatory factors in the bone 
loss of post-menopause or aging, the cytokine production by 
BMA has begun to be assessed. A first antibody-based array study 
indicates that the cytokine content of BMA diverges from that of 
subcutaneous adipocytes with a more pro-adipogenic and pro-
apoptotic profile in aging mice (105). In another independent 
transcriptomic study in mice, BMAs were reported to express 
inflammatory genes, such as TNFα and IL6, at higher levels 
than visceral adipocytes (23). Surprisingly, in both studies, their 
expression levels were downregulated during aging, suggesting 
FiGURe 1 | The bone marrow adipocyte as an active cell in bone remodeling. The bone marrow adipocyte (BMA) can secrete leptin and adiponectin, which 
directly stimulate the proliferation and the differentiation of mesenchymal stem cell (MSC) into osteoblast. Other factors, such as the Wnt signaling inhibitor sFRP1 or 
chemerin, can be released by the BMA: these factors were shown to promote adipogenesis while negatively regulating osteoblastogenesis. As a source of RANKL 
and TNF-α, the BMA can also support osteoclastogenesis. The BMA appears enriched in saturated fatty acids that can trigger the dysfunction and apoptosis of 
osteoblasts. Saturated fatty acids could impact on osteoclast differentiation and survival but results are conflicting. The BMA could release these different factors in 
response to catecholamines, glucocorticoids, and cytokines.
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that this pro-inflammatory profile of BMA is rather early and 
transient. Of note, another transcriptional analysis failed to detect 
any further upregulation of these genes in the BMA from normal-
aged mice fed with a high-fat diet (24). Interestingly, primary 
human femoral BMAs express the pro-osteoclastogenic factor 
RANKL and mediate through a direct cell contact the differentia-
tion of osteoclast precursors (106, 107). RANKL expression was 
also shown to be associated with BMA differentiation and with 
Pref1-expressing preadipocytes in the BM of aging mice (108).
Several in  vitro studies using notably co-culture models 
(109,  110) of BM MSC-derived adipocytes and osteoblasts 
strongly support a deleterious paracrine role of BMA. BM MSC-
derived adipocytes have also been reported to secrete factors 
that alter osteoblastogenesis and favor adipogenesis, such as Wnt 
signaling inhibitors (111) and chemerin (112) (Figure 1).
Metabolic Profile of BMA
Adipocytes synthesize and hydrolyze triglycerides in response 
to insulin and catecholamines, the respective prototypical 
lipogenic and lipolytic factors. Functional assays to establish 
the relative capacity of BMA for lipogenesis and lipolysis 
compared with other fat depots remain scarce due to techni-
cal difficulties. Only one early study in rabbits has reported 
that isolated femoral adipocytes incorporate palmitate into 
triglycerides at level equivalent to perirenal adipocytes (113). 
Catecholamine-induced lipolysis appeared lower in femur 
compared with omental adipose tissue in dogs (114). More 
indirectly, but in line with their small size, mouse BMAs were 
shown to express weaker expression of key genes involved in 
lipogenesis and lipolysis compared with visceral adipocytes (23). 
Moreover, the metabolic activity of BMA has been indirectly 
assessed by the adipocyte size and density determination 
and seems to vary according to their bone localization and 
the different subtypes in rodents. Indeed, only BMA in the 
lumbar spine were affected by a chronic administration of a 
β3-adrenergic agonist (27). In the tibia, cBMA were reported 
resistant to a long-term cold-induced catecholamine challenge 
compared with the regulated subpopulation (29). Whether these 
observations result from the development timing of each BMA 
subset, a different innervation/vascularization of the BM regions 
or intrinsic divergences among BMA subtypes has to be further 
explored. Nevertheless, the relative amount of BMAT compared 
with other adipose tissues supports that the metabolic influence 
of BMA is locally confined.
Importantly, the fatty acid composition of BMA is emerging 
as a key signature of their phenotype. Compared with subcuta-
neous adipose tissue, lipid extracts of human BM (mainly from 
proximal tibia or femur) display a higher proportion of saturated 
fatty acids and a lower amount of monounsaturated ones (115). 
Based on 1H MRS exploration, the unsaturation index of the 
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vertebral fat fraction is decreased compared with controls and 
inversely associated with bone loss (51) or fragility fractures (80) 
in post-menopausal women. Moreover, in healthy adult women, 
a gradual increase of the unsaturation index is observed from the 
proximal femur to the most distal part of the tibia, suggesting a 
differential fatty acid distribution in the BMA subpopulations. 
Accordingly, this was further examined in several bone sites in 
rats to reveal a higher unsaturation index in cBMA compared 
with regulated ones (29). These studies strongly support that 
BMA associated with bone alterations preferentially store satu-
rated fatty acids. This has a strong pathophysiological relevance 
since in vitro chronic exposure of osteoblasts to saturated fatty 
acids triggers their dysfunction and apoptosis (116–118). Results 
are conflicting for the resorbing cells since saturated fatty acids 
were reported either to reduce osteoclastogenesis (119) or to 
exert beneficial effects on mature osteoclasts by preventing their 
apoptosis (120). Though the amount of fatty acids released by 
BMA appears rather low in vitro (121), BMA could contribute to 
bone alterations through a detrimental fatty acid-mediated pro-
cess referred as lipotoxicity. Moreover, a specific lipid pattern of 
BMA may be considered as a discriminative trait, which is rather 
puzzling considering that dietary fat intake usually impacts on 
the fatty acid composition of bone (122), adipose tissues, and 
blood (123). The variation in the BMA fatty acid content could 
reflect an adaptation to systemic metabolic alterations (79, 80) 
and/or an intrinsic characteristic through the expression of 
desaturases (29).
Regulation of BMA Function
Directly assessing the factors regulating the BMA function as 
done through ex vivo experiments with other fat depots is ham-
pered by the dissemination and the scarcity of BMAT in animal 
models. Alternatively, indirect measurements of BMA activity 
through the size and density determination have often been per-
formed using long-term experimentations (27, 29, 40). However, 
in such studies (27, 40), experiments are often carried out while 
BM adipogenesis is also initiated, which may interfere with the 
interpretation of the mature BMA response. One may propose 
to perform tests when BM adiposity (and mostly rBMA) is fully 
developed: indeed, a few interventional studies have already 
uncovered for example a sensitivity to estradiol for BMAT in 
post-menopausal women (124, 125) or to growth hormone for 
tibial rBMA in dwarf rats (126). Moreover, using radiolabeled 
glucose or fatty acid analogs with Positron Emission Tomography 
imaging could be helpful to decipher the metabolic function and 
regulation of BMA during acute challenges. So far, information 
regarding the regulation of BMA function mainly comes from 
in vitro studies (Figure 1).
As mentioned before, like for other WAT, catecholamines 
or agonists of the β-adrenergic receptors stimulate fatty acid 
release from BMA both in  vitro (121, 127, 128) and in  vivo 
(114). Surprisingly, insulin addition does not seem necessary 
for human BM MSC adipogenesis and subsequent lipogenesis 
in vitro (109, 127, 129). However, insulin acutely stimulates glu-
cose uptake (130) and modifies the adipokine pattern (127, 131) 
in  vitro and in organotypic cultures supporting that BMAs are 
sensitive to insulin.
Dexamethasone triggers lipolysis (118) and stimulates the 
secretion of leptin from human BM MSC-derived adipocytes 
(118) or human primary cultivated BMAs (131) like reported 
for extramedullary white adipocytes. Regarding to adiponectin 
secretion, discrepancies are obtained according to the studied 
model (118, 131). Dexamethasone also stimulates the expression 
of RANKL in human primary BMAs (106).
Similarly to white adipocytes, cytokines –  including notably 
TNFα – alter leptin secretion in two cultured models (131, 132), 
supporting that BMAs are also sensitive to a pro-inflammatory 
environment.
CONCLUSiON
Bone marrow adipose tissue is metabolically distinct from other fat 
depots as indicated by several evidence related to its development 
and properties. Numerous data from clinical studies, in vivo, and 
vitro models point to an involvement of BMAT in bone remod-
eling resulting in bone alterations. Besides the participation of 
the adipogenesis process, BMAs are active cells whose phenotype 
is strikingly heterogeneous according to the bone site or BM 
area. Compared with cBMA, rBMA appear highly responsive 
to diverse stimuli. The first characterizations of BMA as well as 
their sensitivity to catecholamines and glucocorticoids support 
that BMA behaves more as a white-like adipocyte whose fatty 
acid or adipokine release could impact on BM cells (Figure 1). 
Moreover, its phenotype could also evolve when bone remodeling 
is altered. Owing to its specific microenvironment, it is expected 
that osteoblasts, osteoclasts, hematopoietic, and other bone cells 
reciprocally regulate BMA function. In that respect, a description 
of BMAT vascularization, innervation, and interaction with BM 
cells is needed to better comprehend its regulation. Moreover, the 
relative contribution of BMAT secretions compared with those of 
extramedullary adipose tissues remains poorly examined, which 
emphasizes the necessity to deepen the characterization of BMA. 
So far considering the different physiopathological situations of 
BMAT development together has not led to a shared hypothesis 
defining the role of BMA. This actually suggests that, as a true 
responsive cell, BMA function and regulation could vary accord-
ing to the pathophysiological context and should be analyzed 
accordingly.
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